Complement C1 Esterase Inhibitor Levels Linked to Infections and Contaminated Heparin-Associated Adverse Events

• Zhao-Hua Zhou,

  Affiliation Division of Monoclonal Antibodies, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Trina Chen,

  Affiliation Division of Monoclonal Antibodies, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Kamalpreet Arora,

  Affiliation Division of Monoclonal Antibodies, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Kenneth Hyams,

  Affiliation Office of Biological Products, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Steven Kozlowski

  * E-mail: Steven.Kozlowski@fda.hhs.gov

  Affiliations Division of Monoclonal Antibodies, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America, Office of Biological Products, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯